Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects

Ji-Young Park, Kyoung Ah Kim, Mun Ho Kang, Su Lyun Kim, Jae Gook Shin

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background and Objective: Rifampin (INN, rifampicin) causes several drug interactions with coadministered antidiabetic drugs. Rosiglitazone is a novel thiazolidinedione antidiabetic drug, but little is known about the drug interaction between rifampin and rosiglitazone. Our objective was to investigate the effect of rifampin on the pharmacokinetics of rosiglitazone in humans. Method: In an open-label, randomized, 2-way crossover study, 10 healthy Korean male subjects were treated once daily for 6 days with 600 mg rifampin or with placebo. On day 7, a single dose of 8 mg rosiglitazone was administered orally. Plasma rosiglitazone concentrations were measured. Results: Rifampin significantly decreased the mean area under the plasma concentration-time curve for rosiglitazone by 65% (2947.9 ng·h/mL versus 991.5 ng·h/mL, P < .001) and the mean elimination half-life from 3.9 to 1.5 hours (P < .001). The peak plasma concentration of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL versus 362.3 ng/mL, P < .01). The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h versus 8.5 L/h, P < .001). Conclusion: This study showed that rifampin affected the disposition of rosiglitazone in humans, probably by the induction of cytochrome P450 (CYP) 2C8 and, to a lesser extent, CYP2C9. Therefore caution should be exercised during the coadministration of rifampin and rosiglitazone.

Original languageEnglish
Pages (from-to)157-162
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume75
Issue number3
DOIs
Publication statusPublished - 2004 Mar 1
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects'. Together they form a unique fingerprint.

  • Cite this